Answers are grounded in this paper and cite their sources.
Regulatory update reports expanded subcutaneous lecanemab approval for initial therapy in Alzheimer's disease, highlighting an alternative to long-term intravenous infusions.
The FDA has approved Leqembi Iqlik, the subcutaneous (SC) formulation of the amyloid beta-directed monoclonal antibody lecanemab, for once-weekly initiation dosing in patients with Alzheimer's disease (AD). The SC formulation was previously approved only for maintenance treatment in patients who had received IV lecanemab for at least 18 months.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: